See more : Sappe Public Company Limited (SAPPE.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Aequus Pharmaceuticals Inc. (AQS.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aequus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tokyo Ichiban Foods Co., Ltd. (3067.T) Income Statement Analysis – Financial Results
- Hiraga Co.,Ltd. (7863.T) Income Statement Analysis – Financial Results
- Putian Communication Group Limited (1720.HK) Income Statement Analysis – Financial Results
- KARNIMATA COLD STORAGE LTD (KCSL.BO) Income Statement Analysis – Financial Results
- Zee Learn Limited (ZEELEARN.NS) Income Statement Analysis – Financial Results
Aequus Pharmaceuticals Inc. (AQS.V)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aequuspharma.ca
About Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 254.90K | 1.38M | 2.71M | 2.59M | 1.63M | 1.41M | 1.14M | 701.63K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 249.40K | 233.39K | 25.78K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.78K | 0.00 | 0.00 |
| Gross Profit | 5.50K | 1.15M | 2.69M | 2.59M | 1.63M | 1.41M | 1.14M | 701.63K | -86.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 2.16% | 83.08% | 99.05% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 301.28K | 168.71K | 296.85K | 54.61K | 210.83K | 526.94K | 894.87K | 1.13M | 2.14M | 1.04M | 1.02M |
| General & Administrative | 2.14M | 2.98M | 1.70M | 1.42M | 1.78M | 2.05M | 3.34M | 2.67M | 2.36M | 1.38M | 408.91K |
| Selling & Marketing | 385.94K | 494.89K | 1.93M | 1.55M | 1.86M | 1.65M | 720.53K | 1.77M | 555.18K | 54.58K | 23.30K |
| SG&A | 2.52M | 3.48M | 3.63M | 2.96M | 3.64M | 3.69M | 4.06M | 4.44M | 2.91M | 1.43M | 432.21K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.96M | 3.64M | 4.06M | 3.12M | 3.85M | 4.22M | 5.05M | 5.57M | 5.06M | 2.48M | 1.64M |
| Cost & Expenses | 3.08M | 3.88M | 4.08M | 3.12M | 3.85M | 4.22M | 5.05M | 5.57M | 5.06M | 2.48M | 1.64M |
| Interest Income | 4.14K | 24.71K | 13.18K | 4.53K | 9.48K | 5.31K | 12.30K | 3.14K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 145.18K | 214.01K | 454.84K | 519.59K | 418.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 138.16K | 129.83K | 128.11K | 210.97K | 309.07K | 187.79K | 187.22K | 172.40K | 86.78K | 1.50K | 749.00 |
| EBITDA | -2.68M | -2.87M | -1.23M | -314.80K | -2.38M | -2.62M | -3.70M | -4.69M | -4.97M | -2.54M | -1.64M |
| EBITDA Ratio | -1,051.95% | -171.64% | -45.17% | -11.98% | -116.34% | -185.73% | -328.51% | -668.28% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.82M | -2.50M | -1.35M | -521.57K | -2.21M | -2.81M | -3.93M | 4.86M | 5.06M | 2.48M | 1.64M |
| Operating Income Ratio | -1,106.45% | -181.05% | -49.89% | -20.12% | -135.28% | -199.04% | -344.94% | 693.18% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -144.44K | -712.01K | -442.14K | -519.26K | -888.21K | 4.29K | 47.91K | 807.00 | 43.75K | 66.12K | 25.42K |
| Income Before Tax | -2.96M | -3.21M | -1.81M | -1.05M | -3.11M | -2.80M | -3.88M | -4.86M | -5.01M | -2.41M | -1.63M |
| Income Before Tax Ratio | -1,163.11% | -232.65% | -66.66% | -40.32% | -190.26% | -198.81% | -340.74% | -693.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.00 | 454.84K | 519.59K | 418.67K | -4.29K | -30.10K | -50.72K | -43.75K | -66.12K | -6.37K |
| Net Income | -2.96M | -3.21M | -1.81M | -1.05M | -3.11M | -2.80M | -3.88M | -4.81M | -5.01M | -2.41M | -1.63M |
| Net Income Ratio | -1,163.11% | -232.65% | -66.66% | -40.32% | -190.26% | -198.81% | -340.74% | -685.84% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.04 | -0.04 | -0.06 | -0.10 | -0.15 | -0.10 | -0.08 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.04 | -0.04 | -0.06 | -0.10 | -0.15 | -0.10 | -0.08 |
| Weighted Avg Shares Out | 132.63M | 132.63M | 128.85M | 93.18M | 80.43M | 75.64M | 67.90M | 47.45M | 34.40M | 25.01M | 21.34M |
| Weighted Avg Shares Out (Dil) | 132.63M | 132.63M | 128.85M | 93.18M | 80.43M | 75.64M | 67.90M | 47.45M | 34.40M | 25.01M | 21.34M |
Source: https://incomestatements.info
Category: Stock Reports